Urology · 2025
Evaluation of the Therapeutic Potential of Garcinia cambogia Alone or in Combination With Silodosin in the Management of LUTS/BPH: A Prospective Randomized Controlled Study.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
El-Shaer Waleed, Abd-Allah Adel Ra, El-Shafie Mohamed F, Salama Ismael M, El Shaer Alaa
Аннотация
OBJECTIVE: To evaluate the efficacy of Garcinia cambogia (hydroxy citric acid) alone or in combination with Silodosin on the clinical outcomes of lower urinary tract symptoms/Benign prostatic hyperplasia (LUTS/BPH).
METHODS: A prospective, randomized, controlled, double-blind study conducted on patients with LUTS/BPH. Eligible patients were assigned randomly to one of three groups. Group A (33 patients) received Silodosin, 8 mg, once daily. Group B (35 patients) received Garcinia extract 500 mg TID. Group C (36 patients) received the combination of Silodosin, plus Garcinia extract. All participants were assessed for the changes in; the maximum urinary flow rate (Qmax), International Prostate Symptom Score (IPSS), Post-Void Residual (PVR), prostate volume (PV), and serum Prostatic Specific Antigen (PSA) levels, at the baseline and after 12 weeks of treatment.
RESULTS: The baseline data regarding Qmax, IPSS, PVR, PV, and PSA showed non-significant differences between the three groups. After 12 weeks of treatment, all groups showed a significant improvement in both Qmax and IPSS (P >.001) and group C showed the best improvement. The PVR was significantly reduced in all groups (P >.001). The PV was significantly increased in group A (P = .006), whereas it was significantly reduced in groups B and C (P >.001). The PSA showed a non-significant increase in group A (P = .625), while it was significantly decreased in groups B and C (P >.001).
CONCLUSION: Treatment with Garcinia extract, especially in combination with Silodosin, may improve the Qmax, IPSS, PVR, PV, and PSA in patients with LUTS/BPH without any clinical significant adverse effects.
METHODS: A prospective, randomized, controlled, double-blind study conducted on patients with LUTS/BPH. Eligible patients were assigned randomly to one of three groups. Group A (33 patients) received Silodosin, 8 mg, once daily. Group B (35 patients) received Garcinia extract 500 mg TID. Group C (36 patients) received the combination of Silodosin, plus Garcinia extract. All participants were assessed for the changes in; the maximum urinary flow rate (Qmax), International Prostate Symptom Score (IPSS), Post-Void Residual (PVR), prostate volume (PV), and serum Prostatic Specific Antigen (PSA) levels, at the baseline and after 12 weeks of treatment.
RESULTS: The baseline data regarding Qmax, IPSS, PVR, PV, and PSA showed non-significant differences between the three groups. After 12 weeks of treatment, all groups showed a significant improvement in both Qmax and IPSS (P >.001) and group C showed the best improvement. The PVR was significantly reduced in all groups (P >.001). The PV was significantly increased in group A (P = .006), whereas it was significantly reduced in groups B and C (P >.001). The PSA showed a non-significant increase in group A (P = .625), while it was significantly decreased in groups B and C (P >.001).
CONCLUSION: Treatment with Garcinia extract, especially in combination with Silodosin, may improve the Qmax, IPSS, PVR, PV, and PSA in patients with LUTS/BPH without any clinical significant adverse effects.